myotwin GmbH looks back on a successful participation at the 30th BIO-Europe in Stockholm. From November 4 to 6, 2024, the event brought together more than 5,500 professionals from over 2,800 companies and more than 60 countries.
myotwin was represented on site by co-founder Andreas Meyer-Borgstädt. For the company, the conference offered a valuable opportunity to engage with partners from pharma and biotech, establish new contacts, and expand existing networks. Compared to previous events, the growing importance of artificial intelligence emerged as a key theme in many discussions. With numerous promising conversations […]
myotwin GmbH participated in this year’s BIO International Convention in San Diego. With more than 19,500 attendees from 70 countries, 1,400 exhibitors, and over 61,000 partnering meetings, the event set new records and reaffirmed its position as the world’s largest biotechnology gathering.
For myotwin, the convention offered a unique opportunity to present its platform of human-based cardiac tissue models in an international context and to engage directly with industry partners and experts. Discussions were particularly shaped by open dialogue on the future of drug development, strategies to reduce animal testing, and new partnership models. Beyond the intensive […]
myotwin GmbH participated in this year’s BIO-Europe in Munich, one of Europe’s leading conferences for the biotechnology and pharmaceutical industries. Over several days, the team took the opportunity to exchange ideas with industry partners and present its platform.
myotwin’s approach of reducing animal testing through realistic human-based models attracted significant attention. The company was represented at BIO-Europe for the first time with its own booth, providing an ideal opportunity to introduce itself to the European biotech community just a few weeks after its founding. With numerous new contacts, promising discussions, and a very […]
The newly founded biotech start-up myotwin GmbH aims to transform drug development for cardiovascular diseases by creating a digital twin of the human heart.
Cardiovascular diseases remain the leading cause of death worldwide and generate healthcare costs in the hundreds of billions each year in Europe alone. Despite this burden, drug development has largely stagnated. One major challenge is the limited reliability of animal models, which differ significantly from the human heart and therefore provide only limited predictive value. […]